Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405699 | 0.92 | TP53 (0.41) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6625524 | 0.87 | MEN1 (0.44) | KDM4EALDH1A1CNR2PLA2G2AGABRP | |
| SCHEMBL6361867 | 0.86 | KMT2A (0.49) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1505647 | 0.85 | TSHR (0.54) | KDM4EALDH1A1TP53POLBTSHR | |
| SCHEMBL28160410 | 0.83 | KDM4E (0.49) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL11453574 | 0.82 | MEN1 (0.47) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11551619 | 0.81 | MEN1 (0.46) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6624700 | 0.81 | CNR2 (0.37) | KDM4ENPC1ALDH1A1RAB9ACNR2 | |
| SCHEMBL27564811 | 0.79 | CNR2 (0.36) | CNR2MAPK8TSHR | |
| SCHEMBL25704057 | 0.79 | POLB (0.42) | KDM4EALDH1A1SMN1; SMN2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015699-A | Heterocyclic urea derivatives and methods of use thereof-211 | ASTRAZENECA AB | 2011-04-13 | — | — | CN | disclosed |
| US-6794387-B2 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (CGMP PDE5) INHIBITORS; 2-(5-ACETYL-2-BUTOXY-3-PYRIDINYL)-7-ETHYL-5-METHYLIMIDAZO(5,1 -F)(1,2,4)TRIAZIN-4(3H)-ONE FOR EXAMPLE | PFIZER INC. | 2004-09-21 | — | — | US | disclosed |
| US-6756373-B1 | SUCH AS 5-(2-BUTOXY-5-IODO-3-PYRIDINYL)-3-ETHYL-2-(2-METHOXY-ETHYL)-2,6-DIHYDRO-7H -PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; ERECTILE DYSFUNCTION | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| EP-1395589-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE 5 INHIBITORS | Pfizer Limited (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1380293-A1 | BONE METABOLISM IMPROVING AGENTS | The Nisshin OilliO, Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-6593332-B2 | Phosphodiesterase inhibitors; sexual disorders | PFIZER INC. | 2003-07-15 | — | — | US | disclosed |
| US-6586439-B2 | Therapy for sexual disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1092719-B1 | Imidazo[5,1-f][1,2,4]triazine derivatives | PFIZER LTD (GB) | 2003-05-28 | — | — | EP | disclosed |
| US-20030013727-A1 | Pharmaceutically active compounds | MAW GRAHAM NIGEL (GB) | 2003-01-16 | — | — | US | disclosed |
| US-6503908-B1 | Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors; sexual disorders | PFIZER INC | 2003-01-07 | — | — | US | disclosed |
| US-20030004173-A1 | Pharmaceutically active compounds | MAW GRAHAM NIGEL (GB) | 2003-01-02 | — | — | US | disclosed |
| US-20020177599-A1 | Pharmaceutically active compounds | PFIZER INC. | 2002-11-28 | — | — | US | disclosed |
| WO-2002079203-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE 5 INHIBITORS | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| US-6440982-B1 | INHIBITORS OF CYCLIC GUANOSINE MONOPHOSPHATE DIESTERASES | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1222190-A1 | 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS | Pfizer Limited (GB) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001027112-A1 | 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| EP-1092718-A1 | 2-(2-Alkoxy-5-heterocyclylsulphonylphenyl)purin-6-ones as phosphodiesterase inhibitors | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-1092719-A2 | Imidazo[5,1-f][1,2,4]triazine derivatives | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004173-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | KDM4E 3234/4885NPC1 1970/4885ALDH1A1 439/4885 |
| US-20020177599-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | KDM4E 2267/4885NPC1 1891/4885ALDH1A1 403/4885 |
| US-20030013727-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | KDM4E 3234/4885NPC1 1970/4885ALDH1A1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.